Merck (MRK) Total Long-Term Assets: $93,670 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRK Merck & Co Inc MRK
72 GF Score
Price $127.47
GF Value $118.80
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Merck Total Long-Term Assets?

Merck MRK +0.96% 72 Total Long-Term Assets is $93,670 Mil as of Mar. 2026. GuruFocus rates MRK with a GF Score™ of 72/100 and a GF Value™ of $118.80 (Fairly Valued). The stock has 8 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Merck's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $93,670 Mil.

Merck Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Merck's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Total Long-Term Assets Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75,428.00 73,438.00 74,507.00 78,324.00 93,350.00

Merck Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79,619.00 80,458.00 81,989.00 93,350.00 93,670.00
MRK
72GF Score
Merck & Co Inc MRK
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $93,670 Mil mean?
Merck (MRK) has a Total Long-Term Assets of $93,670 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Merck and its competitors.
Is Merck's Total Long-Term Assets too high?
Merck's current Total Long-Term Assets is $93,670 Mil. Overall, Merck has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck's Total Long-Term Assets compare to AMGN and ABBV?
Merck's Total Long-Term Assets of $93,670 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Merck and its competitors. Merck's current Total Long-Term Assets is $93,670 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (MRK) is currently considered Fairly Valued. The stock's GF Value™ is $118.80, compared to a current price of $127.47 — trading 7.3% above its estimated fair value. The current Total Long-Term Assets is $93,670 Mil. Merck's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Merck (MRK), the current Total Long-Term Assets is $93,670 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of $127.47 is trading 7.3% above its estimated GF Value™ of $118.80. GuruFocus considers Merck to be Fairly Valued.

Key valuation signals for MRK:

  • Total Long-Term Assets: $93,670 Mil
  • GF Value™: $118.80 vs. price of $127.47 (7.3% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
72GF Score

Get the complete analysis for MRK

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$127.47
Price
$118.80
GF Value